Indexed keywords
BUPRENORPHINE;
FENTANYL;
G PROTEIN COUPLED RECEPTOR;
INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN;
KETAMINE;
LOCAL ANESTHETIC AGENT;
METHADONE;
MORPHINE;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;
NONSTEROID ANTIINFLAMMATORY AGENT;
OPIATE;
OPIATE ANTAGONIST;
PARACETAMOL;
STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;
ANALGESIC AGENT;
GUANINE NUCLEOTIDE BINDING PROTEIN;
NARCOTIC ANALGESIC AGENT;
OPIATE RECEPTOR;
ALLODYNIA;
DISEASE EXACERBATION;
DISEASE SEVERITY;
DRUG MEGADOSE;
DRUG SUBSTITUTION;
HUMAN;
HYPERALGESIA;
LETTER;
PAIN ASSESSMENT;
PRIORITY JOURNAL;
RISK ASSESSMENT;
CHEMICALLY INDUCED DISORDER;
DRUG ADMINISTRATION;
METABOLISM;
NEOPLASM;
NOTE;
PAIN;
ANALGESICS, NON-NARCOTIC;
ANALGESICS, OPIOID;
DRUG ADMINISTRATION SCHEDULE;
GTP-BINDING PROTEINS;
HUMANS;
HYPERALGESIA;
NEOPLASMS;
PAIN;
RECEPTORS, OPIOID;
2
0025788197
Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine
De Conno F, Caraceni A, Martini C, et al: Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 47:337-339, 1991
(1991)
Pain , vol.47
, pp. 337-339
De Conno, F.1
Caraceni, A.2
Martini, C.3
3
0033957306
Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability
Crain SM, Shen KF: Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84:121-131, 2000
(2000)
Pain , vol.84
, pp. 121-131
Crain, S.M.1
Shen, K.F.2
4
0030730101
Opioid-sparing effects of a low-dose infusion of naloxone in patient- administered morphine sulfate
Gan TJ, Ginsberg B, Glass PS, et al: Opioid-sparing effects of a low-dose infusion of naloxone in patient- administered morphine sulfate. Anesthesiology 87:1075-1081, 1997
(1997)
Anesthesiology , vol.87
, pp. 1075-1081
Gan, T.J.1
Ginsberg, B.2
Glass, P.S.3
5
34548285495
Oxytrex: An oxycodone and ultra-low-dose naltrexone formulation
Webster LR: Oxytrex: An oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs 16:1277-1283, 2007
(2007)
Expert Opin Investig Drugs , vol.16
, pp. 1277-1283
Webster, L.R.1
6
33845186402
Oxytrex minimizes physical dependence while providing effective analgesia: A randomized controlled trial in low back pain
Webster LR, Butera PG, Moran LV, et al: Oxytrex minimizes physical dependence while providing effective analgesia: A randomized controlled trial in low back pain. J Pain 7:937-946, 2006
(2006)
J Pain , vol.7
, pp. 937-946
Webster, L.R.1
Butera, P.G.2
Moran, L.V.3
7
20444426267
Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: A randomized, controlled trial of Oxytrex
Chindalore VL, Craven RA, Yu KP, et al: Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: A randomized, controlled trial of Oxytrex. J Pain 6:392-399, 2005
(2005)
J Pain , vol.6
, pp. 392-399
Chindalore, V.L.1
Craven, R.A.2
Yu, K.P.3
8
33947134497
Opioid-induced hyperalgesia: Pathophysiology and clinical relevance
Koppert W: Opioid-induced hyperalgesia: Pathophysiology and clinical relevance. Acute Pain 9:21-24, 2007
(2007)
Acute Pain , vol.9
, pp. 21-24
Koppert, W.1
9
0030860292
Reduction in hyperalgesia and intrathecal morphine requirements by low-dose ketamine infusion
Walker SM, Cousins MJ: Reduction in hyperalgesia and intrathecal morphine requirements by low-dose ketamine infusion. J Pain Symptom Manage 14:129-133, 1997
(1997)
J Pain Symptom Manage , vol.14
, pp. 129-133
Walker, S.M.1
Cousins, M.J.2
10
0036190449
Magnesium increases morphine analgesic effect in different experimental models of pain
Begon S, Pickering G, Eschalier A, et al: Magnesium increases morphine analgesic effect in different experimental models of pain. Anesth 96:627-632, 2002
(2002)
Anesth , vol.96
, pp. 627-632
Begon, S.1
Pickering, G.2
Eschalier, A.3
11
0030904746
Magnesium deficiency induces an hyperalgesia reversed by the NMDA receptor antagonist MK801
Dubray C, Alloui A, Bardin L, et al: Magnesium deficiency induces an hyperalgesia reversed by the NMDA receptor antagonist MK801. Neuroreport 8:1383-1386, 1997
(1997)
Neuroreport , vol.8
, pp. 1383-1386
Dubray, C.1
Alloui, A.2
Bardin, L.3
